Dr. Mesa on the Efficacy of Fedratinib in Patients With Myelofibrosis and Low Platelet Counts

Video

In Partnership With:

Ruben A. Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the efficacy of fedratinib (Inrebic) in patients with myelofibrosis who have low platelet counts.

Ruben A. Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the efficacy of fedratinib (Inrebic) in patients with myelofibrosis who have low platelet counts.

Fedratinib is a JAK2 and FLT3 inhibitor that was approved in August 2019 for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis. Efficacy data from the phase III JAKARTA trial and safety data from the phase II JAKARTA-2 trial served as the basis for the agent’s approval.

Prior to the approval of fedratinib, ruxolitinib (Jakafi) was approved for use at a reduced dose in patients with a platelet count between 50,000 and 100,000. At the 2019 ASH Annual Meeting, investigators looked at the outcomes of patients with a platelet count between 50,000 and 100,000 who received 400 mg of fedratinib.

Results from the pooled analysis of the JAKARTA trials demonstrated that patients with a platelet count between 50,000 and 100,000 and ≥100,000 had a similar symptom resolution rate and spleen response rate, says Mesa. Moreover, 400 mg of daily fedratinib was found to be safe in patients with a platelet count between 50,000 and 100,000. However, several patients developed grade 3/4 thrombocytopenia and required dose modifications, concludes Mesa.

Related Videos
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
Chul Kim, MD, MPH
Neil D. Gross, MD, FACS
Dae Won Kim, MD, Gastrointestinal Oncology Program, Moffitt Cancer Center